Punicalagin Regulates Key Processes Associated with Atherosclerosis in THP-1 Cellular Model

Area of Science:

• Cardiovascular Research
• Nutraceutical Science
• Cell Biology

Background:

• Cardiovascular diseases (CVD) are a leading global cause of death, often stemming from atherosclerosis.
• Nutraceuticals offer a promising avenue for preventing cholesterol deposition and reducing atherosclerotic plaques.
• Punicalagin, a plant-derived phytochemical, is being investigated for its potential therapeutic benefits.

Purpose of the Study:

• To evaluate the anti-atherosclerotic effects of punicalagin in an in vitro cellular model.
• To assess the impact of punicalagin on key inflammatory and cholesterol-related pathways in atherosclerosis.
• To determine the safety and efficacy of punicalagin as a potential nutraceutical intervention.

Main Methods:

• Cytotoxicity assays were performed on THP-1 macrophages using 10 µM punicalagin.
• Real-time PCR analyzed the expression of monocyte chemoattractant protein-1 (MCP-1) and Intercellular adhesion molecule (ICAM-1).
• Monocyte migration and cellular cholesterol efflux assays were conducted to assess punicalagin's functional impact.

Main Results:

• Punicalagin (10 µM) exhibited no significant cytotoxicity on THP-1 macrophages.
• Punicalagin significantly inhibited IFN-γ-induced overexpression of MCP-1 (10-fold) and ICAM-1 (3.49-fold).
• Punicalagin reduced MCP-1-mediated monocyte migration by 28% and enhanced cellular cholesterol efflux by 84-88%.

Conclusions:

• Punicalagin demonstrates significant anti-inflammatory and anti-atherosclerotic properties in vitro.
• The phytochemical effectively modulates key molecular targets and cellular processes involved in atherosclerosis.
• Punicalagin is a safe, non-cytotoxic compound with potential for preventing and treating atherosclerosis.